Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04203316
Title Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Children's Oncology Group
Indications

acute myeloid leukemia

Therapies

Enasidenib

Age Groups: adult | child
Covered Countries USA | CAN

Additional content available in CKB BOOST